Mars Bioimaging Ltd (MBI) was formed in 2007 to commercialize the ground-breaking MARS technology. The MARS system is based on the next generation of x-ray detectors (Medipix3) developed in collaboration with CERN, University of Canterbury, University of Otago, and other partners. MBI has established itself as the world’s leading research and development group in spectral molecular imaging and to-date has delivered the world’s first commercial pre-clinical scanner. In 2014, MBI and its partners were awarded $12M NZD from the New Zealand Ministry of Business, Innovation, and Employment to develop a clinical spectral molecular imaging scanner.